13. Complications: O‐BCS of those compared to S‐BCS.

Study	Wound infection	Flap necrosis	Dehisence	Fat necrosis	Seroma	Skin	Haematoma	Bleeding	Needed surgery
Acea‐Nebril 2017‐VD	1 (0.5%)	4 (2.3%)	‐	‐	3 (1.7%)	‐	4 (2.3%)	3 (1.7%)	(1.7%) ‐ bleeding only
Acea‐Nebril 2005‐VD	2 (4%)	3 (6%)	‐	‐	3 (6%)	‐	4 (8%)	‐	‐
Acosta‐Marin 2014‐VD	1 (1.9%)	‐	‐	1 (1.9%)	‐	1 (1.9%)	‐	‐	‐
Amitai 2018‐VD	‐	‐	‐	15 (22%)	‐	‐	‐	‐	‐
Angarita 2020‐VD	209 (2.3%)	‐	67 (0.7%)	‐	‐	‐	‐	22 (0.3%)	‐
Carter 2016‐VD	45 (4.8%)	‐	‐	‐	126 (13.4%)	‐	18 (1.9%)	‐	‐
Chauhan 2016 (1)‐VD and VR	4 (7%)	2 (3.5%)	‐	‐	1 (1.8%)	‐	1 (1.8%)	‐	‐
Chauhan 2016 (2)‐VD and VR	1 (3.67%)	1 (3.7%)	‐	‐	0 (0%)	‐	1 (3.7%)	‐	‐
Jiang 2015‐VD	‐	‐	1 (3.3%)	‐	3 (10%)	‐	‐	‐	‐
Tang 2016‐VD and VR	0 (0%)	0 (0%)	2 (3%)	0 (0%)	10 (15%)	10 (15%)	3 (4.48%)	0 (0%)	‐
Crown 2019‐VD	15 (3.3%)	‐	14 (3.1%)	‐	8 (1.8%)	2 (0.4%)	‐	‐	‐
DeLorenzi 2016 (1)‐Both	13 (2.8%)	6 (1.3%)	16 (3.5%)	12 (2.6%)	‐	‐	11 (2.4%)	‐	‐
Dolan 2015‐VD and VR	‐	‐	‐	‐	‐	‐	‐	‐	5 (7%)
Down 2013‐VD and VR	2 (5.4%)	‐	‐	‐	‐	‐	‐	‐	breakdown only
Gicalone 2007 (1)‐VD	‐	21 (67%)	5 (16%)	‐	‐	‐	2 (6.45%)	‐	‐
Gicalone 2007 (2)‐VD	‐	‐	2 (5.13%)	‐	‐	1 (2.6%)	1 (2.6%)	‐	‐
Gicalone 2015‐VD	4 (9.52%)	‐	‐	‐	‐	2 (4.8%)	1 (2.4%)	‐	‐
Keleman 2019‐VD	8 (2.3%)	3 (0.9%)	‐	2 (0.57%)	5 (1.4%)	‐	2 (0.6%)	‐	‐
Kimball 2018‐VD	17.7 (2.5%)	33.3 (4.7%)	‐	‐	‐	‐	6.4% (includes seroma)	‐	< 1%
Mazouni 2013 ‐ VD	‐	‐	‐	‐	‐	‐	‐	‐	4 (2%)
Nakada 2019‐VR	‐	68 (16%)	‐	‐	‐	‐	‐	‐	‐
Palsodittlir 2018‐VD and VR	‐	0 (0%)	‐	‐	‐	‐	0 (0%)	‐	‐
Scheter 2019‐VD	‐	‐	2 (16.7%)	1 (8.3%)	‐	‐	‐	‐	0
Tenofsky 2014‐VD	5 (8.6%)	‐	4 (6.9%)	15 (25.9%)	10 (17.2%)	21 (36.2%)	10 (17.2%)	‐	‐
Wijgman 2017‐VD	11 (4%)	‐	‐	‐	17 (6.2%)	‐	31 (11.4%)	‐	6 (1.9%)
Zhou 2019‐VR	‐	‐	‐	‐	3 (9.3%)	‐	0 (0%)	‐	3 (9.3%)

O‐BCS: oncoplastic breast‐conserving surgery
S‐BCS: standard breast‐conserving surgery
VD: volume displacement
VR: volume replacement